In a series of 40 patients treated with L-asparaginase for various neoplastic diseases, 6 patients had generalized anaphylactic reactions to L-asparaginase. Each of these reactors had antibodies detectable by passive hemagglutination, but precipitins were detectable in only one of this group of six patients. That patient had received two courses of the enzyme. 1 wk after the anaphylactic reaction, complement-fixing antibodies were present in all the patients that were studied. Specific reagin antibodies (IgE) were demonstrated in one patient by the release of histamine from his leukocytes after incubation in vitro with Lasparaginase.
INTRODUCTION
Therapy with the enzyme L-asparaginase (Asnase)' from Escherichia coli is an effective means of inducing remission in many patients with acute lymphoblastic and occasional patients with myeloblastic leukemia (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Since the Asnase preparation is a bacterial protein with a molecular weight of about 130,000 (13) and is immunoReceived for publication 28 October 1970 and in revised form 28 December 1970. 'Abbreviations used in this paper: Asnase, L-asparaginase; GRBC, goat red blood cells; ME, mercaptoethanol; PBS, phosphate-buffered saline.
genic in animals (14) (15) (16) , it could be anticipated that a number of patients treated with this agent would develop allergic reactions. In general these have not been severe, but several cases of anaphylactic shock have been reported (4, 8, 17) including a number in our own study (5, 12) .
This report deals with the identification of antibodies formed in man as a result of therapy with Asnase. In particular, it has been found that the presence of passive hemagglutinating antibodies was predictive of impending anaphylaxis especially when such a titer was accompanied by rapid disappearance of the enzyme from the circulation.
METHODS
Source of L-asparaginase. Asnase from E. coli used in this study was obtained from E. R. Squibb & Sons (New York), 180 IU/mg (lots As335-712/15-S-3, 15-S-7, and 15T), as well as from Merck Sharp & Dohme (West Point, Pa), 270 IU/mg (lot C-7941). Erwinia carotovora Asnase was kindly provided by Dr. H. E. Wade of the British Microbiological Research Establishment, 50 IU/mg. All enzyme was supplied as lyophilized powder, which was reconstituted with sterile physiological saline without preservative, immediately before its use.
Assay for enzymatic activity. Enzymatic activity of serum samples was determined by the coupled enzyme reaction of Cooney and Handschumacher (18, 19) . The activity was also measured by quantitating the catalytic decomposition of 5-diazo-4-oxo-L-norvaline at 274 nm (20) .
Both assays were standardized against the Nessler method for the determination of ammonia released from L-asparagine (20) .
Patients. (Table I) . Treatment of patients with Asnase followed the protocol reported by Capizzi et al. (12) . Pa Hyperimmune sera were prepared in 4 kg female, New Zealand white rabbits that were immunized by subcutaneous interscapular injection of 5 mg Asnase in Freund's complete adjuvant (4 ml). Subsequent intravenous booster injections were given 6, 7, and 8 wk after initial immunization. The hyperimmunized animals were anesthetized and exsanguirated; sera from these rabbits were heated to 56°C for 30 min and then frozen in small portions at -70°C.
To demonstrate active enzyme-antibody complexes, 0. (12) . 29 of the patients studied did not have anaphylactic reactions to Asnase. None of these had any serologically detectable specific antibody to the enzyme preparation. In contrast, all six of the patients with generalized anaphylactic reactions had specific passive hemagglutinating antibodies detectable at least 1 day preceding the reaction when those samples were available, and those titers rose in the ensuing days after discontinuation of therapy (Fig. 1) . Patient D. C. developed antibodies after two 1000 IU/kg doses of Asnase but never received further therapy with the enzyme. Four other patients were given no further daily therapy after they developed passive hemagglutination titers.
Both 19S mercaptoethanol-sensitive and 7S mercaptoethanol-resistant antibodies were found in every serum with passive hemagglutinating antibodies. Fig. 2 level of serum antibodies, and a higher, more sustained peak of antibody titer. Moreover, as shown in Fig. 4 . when sucrose gradient ultracentrifugation was performed on serum drawn 12 days after the reaction, 7S mercaptoethanol-resistant antibody was found to predominate with relatively little antibody activity in the 19S-sedimenting fractions. Antibody that sedimented in the 7S region was found to predominate even on the 1st day of appearance of a passive hemagglutination titer. This response was in sharp contrast with patients that had been given only one course of enzyme. These findings suggest that lymphocytes of patient E. S. had been "primed" to produce antibodies by the low doses of Asnase during the first course even though serum antibodies were not detectable at that time.
Plasmiia levels of asparafyiasc. Plasma levels of [3] [4] IUjiml of Asnase were generally observed 24 hr after intravenotus administration of 200 lU,/kg per day. In patients wNho had an anaphylactic reaction, the plasma Asnase level fell 1-3 days before the reaction (Fig. 1 Precipitation of antigen-antibody complexes formed in vitro. The ability of Asnase to form complexes with antibody was tested in vitro with sera from several patients. 2 IU of Asnase was added to 1 ml of serum in which free passive hemagglutinating antibody was detectable, and the mixture was incubated for 30 min at 4VC. Controls included incubation of Asnase with sera taken before the onset of therapy, and immune sera to which no Asnase was added. 30% saturation with (NH4)2SO4 was found to insolubilize the complexes formed. Only complexed antigen and antibody were differentially precipitated at 30% saturation, whereas Asnase and unbound immunoglobulins remained soluble. At 40% saturation or more, both free Asnase and unbound immunoglobulins were precipitated together with the complexes. Double diffusion in agar against specific goat antihuman globulins identified the classes of antibody present in the precipitate. By this means IgA, IgM, and IgG all were found in 30% saturated (NH4)2SO4 precipitates containing specific antibody and Asnase. Unfortunately, we could not identify complexes that may have been formed in vivo in sera immediately antedating the time of anaphylaxis by direct 30% saturated ammonium sulfate fractionation, probably because the levels were too low to detect. It should be noted that Asnase activity was still detectable in the complex and, in fact, was found there almost exclusively rather than in the supernatant fluid of samples from the three patients tested on days after their anaphylactic reactions (Fig.  5) .
Inactivation of enzyme by rabbit antibody. Use of a high titered rabbit antiserum to the same preparations of Asnase used in our patients enabled us to demonstrate why Asnase activity was not lost in precipitates of antigen-antibody complexes. As shown in Fig. 6 , it proved impossible to inactivate the sample containing the enzyme and antibody beyond 50% of the enzyme activity even at antibody excess. When the samples were centrifuged, all of the activity was found to be in the precipitate. A similar result was also obtained with serum from patient E. S.
Reaction of antibody with pure enzyme. In order to determine whether at least a portion of the antibodies made in these patients was to the enzyme itself rather than solely to contaminants in the therapeutic preparation, 10 IU of Asnase (antigen excess) was incubated with 0.5 ml of serum from patient E. S. (day 22) for 30 min at 370C. The mixture was fractionated on a 10-40% linear sucrose gradient. As a control, serum obtained on a day previous to the initiation of therapy in which no antibody was detectable, was incubated with the same amount of Asnase. Free Asnase was found in the 7S region of the control gradient, but a shift of Asnase activity was identified in the experimental gradient, consistent with the formation of a complex more dense than the enzyme alone (Fig. 7) . The smearing of activity suggested various degrees of itself (Fig. 8) . A preparation of Asnase essentially homogeneous by electrophoresis showed only a single line of identity with the innermost line of the less pure preparation. Asnase from E. carotozora did not slhow anly crossreaction with E. coli Asnase by this method. However, when serum from a rabbit immunized against E. carotovora Asnase was tested against GRBC's sensitized with E. coli Asnase, a titer of 3 was obtained. It must therefore be concluded that mild cross-reactivitv exists between Asnase's from these two bacterial sources.
Comnplemenzt-fixinig anitibodics. Sera froim five patients with immunological reactions were tested, and all had complement-fixing antibodies to the Asnase preparation demonstrable on the 12th day after initiation of therapy and thereafter. The optimal concentration of Asnase for this test was approximately 0.125 jug/ml.
Reagins (IgE). Attempts to demonstrate a quantitative increase in serum IgE by microimmunodiffusion were unsuccessful in all of our patients. However, histamine release was demonstrable after incubation of peripheral blood leukocytes from patient A. R. with Asnase in vitro, indicative of cell-bound IgE (Fig. 9) This may be attributable to the cytotoxic agents many of these children were receiving when the histamine release assay was performed. An indirect test passively sensitizing normal leukocytes with sera from these patients may circumvent this difficulty (29) . Since the test for reagins by histamine release was complex and was limited by the low histamine content of the leukocytes, this procedure was not useful in this study to document the presence of IgE antibodies in reactors. Skin testing was likewise rejected because, aside from the hazard of eliciting a severe anaphylactic reaction by skin testing, a further serious objection is its failure to predict absolutely whether allergic reactions will occur when the agent tested is given by a route other than intradermally. It has been shown by others (30) that complement-fixing antibodies bear no apparent relationship to either the tissue sensitizing reagins or to socalled "blocking" antibodies, the IgG antibodies produced in high titer during desensitization procedures, but which may also be formed during the natural course of allergic sensitization (31) .
There is ample precedent for using passive hemagglutination as a method of detecting antibodies associated with allergic reactions to drugs or foreign proteins (32, 33) as well as to pollen allergens (34, 35) . Extensive investigations by Sehon, Gyenes, and Kisil (31) have indicated that passive hemagglutinating antibodies against ragweed pollen are more closely correlated with IgG antibodies than with IgE antibodies. Nevertheless, it appears from this study that reaginic antibodies and passive hemagglutinating antibodies to Asnase are produced simultaneously in man and that, therefore, the passive hemagglutination reaction may be useful in predicting serious anaphylaxis. A simultaneous rise in reagins and "other antibodies" was also found by others using different methods (36) . In the current study, the rise in antibody titer was particularly striking when coupled with a rapid fall in previously stable levels of Asnase in the serum. It is suggested that this fall was a manifestation of accelerated clearance of antigen-antibody complexes by the reticuloendothelial system. A recent preliminary report, however, (37) has indicated a lack of correlation between decreased enzyme levels and allergic reactions. Although only one patient in our series did not manifest such an association, passive hemagglutinating antibodies were not determined in the other study, and it is thus difficult to make a direct comparison with those results. It remains to be determined whether minor anaphylactoid reactions such as urticaria may occur after passive hemagglutinating antibodies appear in the serum as suggested by patient L. T. in this study, or whether a degree of sensitization sufficient to cause a positive passive hemagglutination titer invariably leads to anaphylactic shock.
Although precipitin lines could not always be detected by the Ouchterlony technique, in contrast with two other reports in which a higher incidence of precipitin formation was observed (17, 38) , the precipitation of soluble complexes of Asnase and antibody with 30% saturated ammonium sulfate after previous addition of Asnase to serum with a positive passive hemagglutination titer, demonstrated that such complexes were formed. Considerable amounts of IgG and IgM antibodies were detectable in the antigen-antibody complexes precipitated with 30% saturated ammonium sulfate. The unavailability of an antiserum against IgE at the time of this study precluded the demonstration of reagins that may also have been present in the complexes. Both precipitates and soluble complexes retained enzymatic activity, and it was impossible to inactivate the enzyme beyond 50% even in the zone of antibody excess. A similar lack of complete inactivation by immune serum has been reported (39) . This indicates that the antibody does not bind directly at the active site of the enzyme but may limit accessibility of the substrate to the active site. Furthermore, Asnase inactivated by a specific active site reagent, 5-diazo-4-oxo-L-norvaline (20) , gave a line of identity with native Asnase by Ouchterlony double diffusion in agar. Since the enzyme is a tetramer with four catalytic sites (20) , the antigenantibody complex may still leave an active site exposed. Sequestration of enzymatically active antigen-antibody complexes in the reticuloendothelial system might thus account for the prolonged absence of L-asparagine in the plasma after the disappearance of detectable levels of Asnase in the circulation (12, 40) .
